Halozyme Therapeutics Inc Earnings

The next earnings date for Halozyme Therapeutics Inc is October 29, 2025.

They are scheduled to announce earnings before the market opens that day.

Analyst Estimates of Halozyme Therapeutics Inc Earnings

Report DateEstimated Earnings Per Share
10/29/2025$1.43

What is an Earnings Date

An earnings date is typically considered to be the date that a company publicly announces its earnings. Many companies in the US stock market do earnings announcements once per quarter.

Earnings announcements are typically accompanied by commentary from the company that explains the earnings performance and speaks to future earnings prospects.

Earnings announcements can cause a company’s stock price to change abruptly, so earnings dates are closely monitored by some investors.

Halozyme Therapeutics Inc Earnings: Historical

Report DateBefore/After MarketEarnings Per ShareSurprise %
08/05/2025---$1.5424.19%
05/05/2025Before Market$1.1114.20%
02/18/2025Before Market$1.268.73%
10/31/2024After Market$1.2729.59%
08/06/2024After Market$0.9119.74%
05/07/2024After Market$0.7912.86%
02/20/2024After Market$0.82-1.20%
11/06/2023After Market$0.755.63%
08/08/2023After Market$0.7417.46%
05/09/2023After Market$0.47-2.08%
02/21/2023After Market$0.482.13%
11/08/2022After Market$0.7445.10%
08/09/2022After Market$0.536.00%
05/10/2022After Market$0.47-4.08%
02/22/2022After Market$0.422.44%
11/02/2021After Market$0.5121.43%
08/09/2021After Market$0.6251.22%
05/10/2021After Market$0.3715.63%
02/23/2021After Market$0.50-5.66%
11/02/2020After Market$0.2531.58%
08/10/2020After Market$0.19-24.00%
05/11/2020After Market$-0.04-100.00%
02/24/2020After Market$-0.24-60.00%
11/12/2019After Market$-0.17-41.67%
08/06/2019After Market$-0.1028.57%
05/07/2019After Market$0.010.00%
02/21/2019After Market$-0.0166.67%
11/06/2018After Market$-0.1917.39%
08/07/2018After Market$-0.1627.27%
05/10/2018After Market$-0.1913.64%
02/20/2018After Market$0.8518.06%
11/07/2017After Market$0.02120.00%
08/08/2017After Market$-0.234.17%
05/09/2017After Market$-0.26-4.00%
02/28/2017After Market$-0.2125.00%
11/07/2016After Market$-0.2314.81%
08/09/2016After Market$-0.2122.22%
05/09/2016After Market$-0.1620.00%
02/29/2016After Market$0.03142.86%
11/09/2015After Market$-0.19-18.75%
08/10/2015After Market$0.02122.22%
05/11/2015After Market$-0.127.69%
03/02/2015After Market$-0.0433.33%
11/10/2014After Market$-0.16-14.29%
08/11/2014---$-0.137.14%
05/12/2014---$-0.22-57.14%
02/27/2014---$-0.19-18.75%
11/08/2013---$-0.17-13.33%
08/07/2013---$-0.20-53.85%
05/08/2013---$-0.17-13.33%
02/25/2013---$-0.0473.33%
11/08/2012---$-0.18-28.57%
08/06/2012---$-0.1313.33%
05/07/2012---$-0.14-27.27%
03/09/2012---$-0.18-20.00%
11/07/2011---$0.05225.00%
08/05/2011---$0.03123.08%
05/06/2011---$-0.1016.67%
03/11/2011---$-0.17---
11/05/2010---$-0.137.14%
08/06/2010---$-0.137.14%
05/07/2010---$-0.1318.75%
03/12/2010---$-0.1417.65%
11/06/2009---$-0.1611.11%
08/07/2009---$-0.21-23.53%
05/08/2009---$-0.18-12.50%
03/13/2009---$-0.21-61.54%
11/06/2008---$-0.14-7.69%
08/08/2008---$-0.14-7.69%
05/08/2008---$-0.13-8.33%
03/13/2008---$-0.11-37.50%
11/08/2007---$-0.09-50.00%
08/09/2007---$-0.07-75.00%
05/10/2007---$-0.050.00%
03/08/2007---$-0.07-16.67%
11/09/2006---$-0.060.00%
08/10/2006---$-0.050.00%
05/10/2006---$-0.06-20.00%
03/23/2006---$-0.07-16.67%
11/11/2005---$-0.07-16.67%
08/08/2005---$-0.060.00%
05/13/2005---$-0.060.00%
03/09/2005---$-0.0528.57%
11/12/2004---$-0.08-60.00%
08/16/2004---$-0.05-25.00%
06/01/2004---$-0.08-177.33%
03/30/2004---$-0.01---

More About Halozyme Therapeutics Inc

Website
https://halozyme.com
Country
USA
Full Time Employees
350

Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous (SC) administration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company offers Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for chronic lymphocytic leukemia treatment; HYQVIA to treat primary immunodeficiency disorders; Ocrevus (ocrelizumab) for multiple sclerosis; N6LS and cabotegravir to treat HIV; DARZALEX to treat amyloidosis, and smoldering and multiple myeloma; Epinephrine Injection to treat allergic reactions; nivolumab and relatlimab to treat solid tumors; teriparatide injections; OTREXUP, an SC methotrexate injection for severe active rheumatoid arthritis, severe recalcitrant psoriasis, and active polyarticular juvenile idiopathic arthritis; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. The company has collaborations and licensing agreements with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc.; Takeda Pharmaceuticals International AG and Baxalta US Inc; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol Myers Squibb Company; argenx BVBA; ViiV Healthcare; Chugai Pharmaceutical Co., Ltd.; and Acumen Pharmaceuticals, Inc. The company was founded in 1998 and is headquartered in San Diego, California.

“Halozyme Therapeutics Inc Earnings” Can Refer to the Halozyme Therapeutics Inc Earnings Date

Some people say “Halozyme Therapeutics Inc earnings” as a shortform way to refer to the earnings date.

For example, someone might say, “I plan to hold my Halozyme Therapeutics Inc position through earnings.” That typically means the person is going to hold their position through the upcoming earnings date.

Owning Halozyme Therapeutics Inc Stock on the Earnings Date

If you own Halozyme Therapeutics Inc stock (HALO) on the earnings date, then you will be exposed to the potential price volatility that often accompanies earnings announcements.

A company’s earnings typically have a big impact on its stock price, which explains why the stock price for Halozyme Therapeutics Inc might exhibit major fluctuations on the day of the earnings announcement. The price fluctuations can go in either direction (up or down), representing a larger potential investment risk and reward than many other days of the year.

There is often a big audience of investors involved with trading Halozyme Therapeutics Inc shares of stock on its earnings day. This means there is typically more trading volume, liquidity, and price volatility on the day earnings are announced.

These features are attractive to some types of active traders who are looking for stocks that exhibit large price movements and substantial volume.

Learning More Halozyme Therapeutics Inc Earnings

You can contact us any time if you would like to ask questions about Halozyme Therapeutics Inc earnings or anything else related to the stock market.